American Society of Hematology

How I Treat MGUS and Smoldering Myeloma

Jesús San Miguel, MD, PhD, University of Navarra

Saturday, September 9, 2017 2:30 p.m.
Fairmont Chicago, Millennium Park, Chicago, IL

The risk of progression of smoldering multiple myeloma (SMM) to active multiple myeloma is not uniform, and several markers may contribute to identify patients at high risk of progression (less than 50 percent progressions within two years). The definition of multiple myeloma has recently been revisited, and a subgroup of high-risk patients at 70 to 80 percent risk of progression at two years are now considered to be active multiple myeloma candidates for treatment. Although the current standard of care for SMM is not to treat, a randomized trial in high-risk SMM patients comparing early treatment versus observation has shown a significant benefit in terms of time to progression and overall survival for early intervention. Dr. San Miguel will review the most valuable biomarkers for accurate risk stratification in order to plan an optimized follow-up according to the risk of progression, as well as clinical trials investigating early treatment in high-risk SMM.

About the Speaker

Jesus San Miguel

Jesús San Miguel, MD, PhD, is Professor of Medicine (Hematology), Director of Clinical and Translational Medicine at the University of Navarra in Spain. He is currently the President of the International Myeloma Society. Dr. San Miguel has made important contributions to myeloma cell biology (immunophenotyping, risk of progression of SMM, minimal residual disease) and in the area of therapeutics (proteasome inhibitors, IMiDs, histone deacetylases). He has published more than 700 original papers covering a broad range of topics on myeloma biology and therapeutics.

back to top